Growth hormone and insulin-like growth factor I responses to moderate submaximal acute physical exercise in man: effects of octreotide, a somatostatin analogue, administration

What Was Tested

This controlled clinical trial looks at Octreotide.

The researchers evaluated growth hormone (GH) and insulin-like growth factor I (IGF-I) response to moderate submaximal acute short-term physical exercise under basal conditions and after the administration of octreotide, a somatostatin analogue (SA), in a double-blind, counter-balanced experimental protocol.

Before starting the exercise test all the subjects received a single administration of placebo or octreotide and vice versa at two different sessions.

Who Took Part

The age groups tagged for this paper are adults, men only.

How the Study Was Run

The researchers set it up as a double-blind and placebo-controlled study.

Blinding on both sides kept the participants and researchers unaware of who received Octreotide.

The comparison arm used a placebo, so changes seen with Octreotide could be set against what happens without it.

Plasma GH, IGF-I and lactate assays were evaluated before starting, during, at the end and in the recovery phase.

What Was Measured

The researchers evaluated growth hormone (GH) and insulin-like growth factor I (IGF-I) response to moderate submaximal acute short-term physical exercise under basal conditions and after the administration of octreotide, a somatostatin analogue (SA), in a double-blind, counter-balanced experimental protocol.

Before starting the exercise test all the subjects received a single administration of placebo or octreotide and vice versa at two different sessions.

PubMed files the paper under topics including Analysis of Variance, Area Under Curve, Exercise Test, Heart Rate, Hormones, Human Growth Hormone and Insulin-Like Growth Factor I.

What This Means in Plain Language

The paper is a double-blind and placebo-controlled study of Octreotide.

The publication is from 1997 (International journal of sports medicine), a journal based in Germany.

More context: the Octreotide compound page, all human trials.